Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.31 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17472656 | 0.80 | NR1H2 (0.40) | NR1H2 | |
| SCHEMBL13571267 | 0.79 | SLC7A5 (0.32) | BRD4SLC7A5NR1H2MBOAT4 | |
| SCHEMBL533688 | 0.78 | SLC7A5 (0.34) | BRD4SLC7A5 | |
| SCHEMBL534536 | 0.78 | NR1H2 (0.34) | SLC7A5NR1H2HTR2CSLC6A4 | |
| SCHEMBL14686051 | 0.76 | CYP1A2 (0.44) | BRD4SLC7A5NR1H2MRGPRX4 | |
| SCHEMBL12982974 | 0.75 | PTGER2 (0.62) | — | |
| SCHEMBL533746 | 0.75 | SSTR4 (0.33) | GRM2 | |
| SCHEMBL533563 | 0.73 | SSTR4 (0.34) | GRM2 | |
| SCHEMBL535048 | 0.72 | PTGER2 (0.60) | — | |
| SCHEMBL3458984 | 0.72 | PTGER2 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676720-B2 | Substituted biaryl compound | UBE INDUSTRIES, LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-20160213657-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PULMONARY DISEASE | UBE INDUSTRIES, LTD. (JP) | 2016-07-28 | — | — | US | disclosed |
| EP-3042656-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PULMONARY DISEASE | UBE Industries, Ltd. (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160060221-A1 | SUBSTITUTED BIARYL COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2016-03-03 | — | — | US | disclosed |
| EP-2980075-A1 | SUBSTITUTED BIARYL COMPOUND | UBE Industries, Ltd. (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| EP-2476668-B1 | ANILINE COMPOUNDS | UBE INDUSTRIES (JP) | 2013-11-06 | — | — | EP | disclosed |
| EP-2520570-A1 | AMINOPYRIDINE COMPOUND | Ube Industries, Ltd. (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| EP-2476678-A1 | SUBSTITUTED CARBONYL COMPOUNDS | Ube Industries, Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| EP-2476668-A1 | ANILINE COMPOUNDS | Ube Industries, Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060221-A1 | SUBSTITUTED BIARYL COMPOUND | FIBP, FGF2, FGFR2 | BRD4 36/4885GRM2 4256/4885SLC7A5 672/4885 |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | BRD4 840/4885GRM2 554/4885SLC7A5 1619/4885 |
| US-20160213657-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PULMONARY DISEASE | CFTR, ADRB3, ADRB2 | BRD4 662/4885GRM2 2684/4885SLC7A5 1336/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | BRD4 932/4885GRM2 567/4885SLC7A5 1531/4885 |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | PTGIS, QDPR, PTGIR | BRD4 1503/4885GRM2 923/4885SLC7A5 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.